Behavioral intervention boosts physical activity in breast cancer survivors
the ONA take:
The Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) trial was a multicenter trial including 692 overweight or obese women who had breast cancer.
Obesity is known to increase risk for all-cause mortality and breast cancer mortality among women in whom the disease was diagnosed and treated. This study is the largest trial on weight loss intervention among survivors of breast cancer.
The women had undergone primary treatment for early stage breast cancer, on average, 2 years before enrollment in the study.
They were randomly assigned to a group-based behavior intervention, including telephone counseling and tailored newsletters, or a less intensive control intervention. Both groups were observed for 2 years, with weight and blood pressure measurements taken at 6, 12, 18, and 24 months.
At 12 months, weight loss was greater in the intervention group than in the control group (6.0% of initial weight vs. 1.5%, respectively).
At 24 months, weight loss was also greater in the intervention group (3.7%) compared with the control group (1.3%). Effects on physical activity and blood pressure were favorable in the intervention group as well.
The study findings demonstrated that a behavioral weight loss intervention can produce clinically meaningful weight loss in overweight/obese breast cancer survivors.
Further studies are needed to test methods for sustained weight loss and to determine the potential benefits of intentional weight loss in this patient population.
A behavioral weight loss intervention can produce clinically meaningful weight loss in overweight/obese breast cancer survivors.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|